Your browser version may not work well with NCBI's Web applications. More information here...
1: Breast Cancer Res. 2000;2(3):176-83. Epub 2000 Mar 25.
Related Articles, Links
Click here to read Click here to read
Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.

Stern DF.

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520-8023, USA. Stern@biomed.med.yale.edu

ERBB family receptor tyrosine kinases are overexpressed in a significant subset of breast cancers. One of these receptors, HER2/neu, or ErbB-2, is the target for a new rational therapeutic antibody, Herceptin. Other inhibitors that target this receptor, and another family member, the epidermal growth factor (EGF) receptor, are moving into clinical trials. Both of these receptors are sometimes overexpressed in breast cancer, and still subject to regulation by hormones and other physiological regulators. Optimal use of therapeutics targeting these receptors will require consideration of the several modes of regulation of these receptors and their interactions with steroid receptors.

Publication Types:
PMID: 11250707 [PubMed - indexed for MEDLINE]

PMCID: PMC138772